Barry P W, O'Callaghan C
Department of Child Health, University of Leicester, Leicester Royal Infirmary, UK.
Thorax. 1996 Aug;51(8):835-40. doi: 10.1136/thx.51.8.835.
A study was performed to determine in vitro the difference in drug output of seven currently available spacer devices when used with different inhaled medications.
A glass multistage liquid impinger (MSLI) was used to determine the amount of disodium cromoglycate (DSCG, 5 mg), salbutamol (100 micrograms), or budesonide (200 micrograms) obtained in various particle size ranges from metered dose inhalers (MDIs) actuated directly into the MSLI or via one of seven different spacer devices; the Fisonair, Nebuhaler, Volumatic, Inspirease, Aerochamber, Aerosol Cloud Enhancer, and Dynahaler.
In particles smaller than 5 microns in diameter the dose of DSCG recovered from the Fisonair and Nebuhaler was 118% and 124%, respectively, of that recovered using the MDI alone. The dose recovered from the smaller volume spacers was 90% (Inspirease), 36% (Aerochamber), 33% (Aerosol Cloud Enhancer), and 21% (Dynahaler) of that from the MDI alone. The Volumatic increased the amount of salbutamol in particles smaller than 5 microns to 117% of that from the MDI, and the Inspirease and Aerochamber spacers decreased it by nearly 50%. The amount of budesonide in small particles recovered after use of the Nebuhaler, Inspirease, and the Aerochamber was 92%, 101%, and 78%, respectively, of that from the MDI alone.
Under the test conditions used, large volume spacers such as the Fisonair, Nebuhaler, and Volumatic delivered significantly more DSCG and salbutamol than the smaller spacers tested. The differences between spacers were less for budesonide than the other medications studied. This study shows that there are significant differences in the amount of drug available for inhalation when different spacers are used as inhalational aids with different drugs. Spacer devices need to be fully evaluated for each drug prescribed for them.
开展了一项研究，以在体外确定七种现有储雾罐装置与不同吸入药物联用时药物输出的差异。
使用玻璃多级液体撞击器（MSLI）来测定色甘酸钠二钠（DSCG，5毫克）、沙丁胺醇（100微克）或布地奈德（200微克）在不同粒径范围内的量，这些药物通过直接喷入MSLI或经由七种不同储雾罐装置之一（Fisonair、Nebuhaler、Volumatic、Inspirease、Aerochamber、气雾剂云增强器和气雾吸入器）从定量吸入器（MDI）中获得。
在直径小于5微米的颗粒中，从Fisonair和Nebuhaler回收的DSCG剂量分别是仅使用MDI时回收剂量的118%和124%。从小容量储雾罐回收的剂量分别是仅使用MDI时回收剂量的90%（Inspirease）、36%（Aerochamber）、33%（气雾剂云增强器）和21%（气雾剂吸入器）。Volumatic使直径小于5微米颗粒中的沙丁胺醇量增加到MDI的117%，而Inspirease和Aerochamber储雾罐使其减少了近50%。使用Nebuhaler、Inspirease和Aerochamber后回收的小颗粒中布地奈德的量分别是仅使用MDI时回收量的92%、101%和78%。
在所使用的测试条件下，Fisonair, Nebuhaler和Volumatic等大容量储雾罐输送的DSCG和沙丁胺醇比所测试的小容量储雾罐显著更多。布地奈德储雾罐之间的差异小于所研究的其他药物。这项研究表明，当不同储雾罐用作不同药物的吸入辅助装置时，可供吸入的药物量存在显著差异。对于为其开具的每种药物，储雾罐装置都需要进行全面评估。
